PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades

(2021) Yongrong Yan et al.   Aging-US

MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage

(2021) Peter Kalev et al.   CANCER CELL

The impact of multi-agent chemotherapy in metastatic pancreatic adenocarcinoma: A population-based study utilizing the SEER database.

(2021) Kavin Sugumar et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

(2021) Talia Golan et al.   JOURNAL OF CLINICAL ONCOLOGY

PRMT5 inhibition disrupts splicing and stemness in glioblastoma

(2021) Patty Sachamitr et al.   Nature Communications

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

(2021) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Protein arginine methylation: from enigmatic functions to therapeutic targeting

(2021) Qin Wu et al.   NATURE REVIEWS DRUG DISCOVERY

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

(2021) T. Conroy et al.   ANNALS OF ONCOLOGY

Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model

(2020) Anouk E. J. Latenstein et al.   ANNALS OF SURGICAL ONCOLOGY

Protein arginine methyltransferase 5 promotes cholesterol biosynthesis–mediated Th17 responses and autoimmunity

(2020) Lindsay M. Webb et al.   JOURNAL OF CLINICAL INVESTIGATION

HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).

(2020) Margaret A. Tempero et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

(2020) Michael J Pishvaian et al.   LANCET ONCOLOGY

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

(2020) Michelle Chan-Seng-Yue et al.   NATURE GENETICS

High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer

(2020) Lei Tan et al.   Aging-US

PRMT5 silencing selectively affects MTAP ‐deleted mesothelioma: In vitro evidence of a novel promising approach

(2020) Marcella Barbarino et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

NTRK gene fusions in bilio-pancreatic cancers.

(2020) Anne Demols et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.

(2020) Andrew Eugene Hendifar et al.   JOURNAL OF CLINICAL ONCOLOGY

The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.

(2020) Kyaw Thein et al.   JOURNAL OF CLINICAL ONCOLOGY

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

(2020) Bruno Bockorny et al.   NATURE MEDICINE

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

(2020) Holly Brunton et al.   Cell Reports

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening

(2020) Carol Cremin et al.   Cancer Medicine

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

(2020) Przemysław Duda et al.   Cells

Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer

(2020) Luisa F. Escobar-Hoyos et al.   CANCER CELL

Metastatic Pancreatic Cancer: ASCO Guideline Update

(2020) Davendra P.S. Sohal et al.   JOURNAL OF CLINICAL ONCOLOGY

PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity

(2020) Hyungsoo Kim et al.   Science Translational Medicine

Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

(2020) Rachel L. Palte et al.   ACS Medicinal Chemistry Letters

Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer

(2020) David Shifteh et al.   Cancers

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

(2020) D.J. Renouf et al.   ANNALS OF ONCOLOGY

537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

(2020) M. Vieito Villar et al.   ANNALS OF ONCOLOGY

EZH2 regulates pancreatic cancer subtype identity and tumor progression via transcriptional repression of GATA6

(2020) Shilpa Patil et al.   CANCER RESEARCH

Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics

(2020) James T. Topham et al.   CLINICAL CANCER RESEARCH

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

(2020) Xiaolong Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer

(2020) Tzuriel Sapir et al.   MOLECULAR CANCER RESEARCH

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification

(2020) Pilar Espiau-Romera et al.   Journal of Clinical Medicine

PRMT1 loss sensitizes cells to PRMT5 inhibition

(2019) Guozhen Gao et al.   NUCLEIC ACIDS RESEARCH

Protein Arginine Methyltransferase 5 (PRMT5) Promotes Survival of Lymphoma Cells via Activation of WNT/β-CATENIN and AKT/GSK3β Proliferative Signaling

(2019) Jihyun Chung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

(2019) Yi Qin et al.   Cell Communication and Signaling

Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia

(2019) Eric Wang et al.   CANCER CELL

Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

(2019) Ashton A. Connor et al.   CANCER CELL

NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma

(2019) Martin R Jones et al.   CLINICAL CANCER RESEARCH

PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells

(2019) Fen Zhu et al.   LEUKEMIA

Discovery of Potent and Selective Covalent Protein Arginine Methyl-transferase 5 (PRMT5) Inhibitors.

(2019) Hong Lin et al.   ACS Medicinal Chemistry Letters

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

(2019) Andrew Fedoriw et al.   CANCER CELL

Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level

(2019) Sunil Kumar Tewary et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

The regulation, functions and clinical relevance of arginine methylation

(2019) Ernesto Guccione et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

(2019) Talia Golan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hallmarks of ribosomopathies

(2019) Kim R Kampen et al.   NUCLEIC ACIDS RESEARCH

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

(2019) Eileen M. O’Reilly et al.   JAMA Oncology

Arginine methylation expands the regulatory mechanisms and extends the genomic landscape under E2F control

(2019) Alice Poppy Roworth et al.   Science Advances

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma

(2019) Chengkun Yang et al.   Frontiers in Oncology

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation

(2019) Jia Yi Fong et al.   CANCER CELL

Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer

(2019) Joanna M. Karasinska et al.   CLINICAL CANCER RESEARCH

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer

(2019) Min Yu et al.   Frontiers in Oncology

438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

(2019) L L Siu et al.   ANNALS OF ONCOLOGY

Selective PRMT5 inhibitors suppress human CD8+ T-cells by upregulation of p53 and impairment of the AKT pathway similar to the tumor metabolite MTA

(2019) Carolin Dorothea Strobl et al.   MOLECULAR CANCER THERAPEUTICS

PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia

(2019) Aliaksandra Radzisheuskaya et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

PRMT5 promotes epithelial‐mesenchymal transition via EGFR‐β‐catenin axis in pancreatic cancer cells

(2019) Lu Ge et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

(2019) Robert C Doebele et al.   LANCET ONCOLOGY

Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy

(2019) Xuesen Dong et al.   ONCOGENE

Pancreatic cancer organoids recapitulate disease and allow personalized drug screening

(2019) Else Driehuis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2019) Akram Pourshams et al.   Lancet Gastroenterology & Hepatology

Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling

(2018) Pengyu Jing et al.   CANCER LETTERS

Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative

(2018) Michael J. Pishvaian et al.   CLINICAL CANCER RESEARCH

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

(2018) Maeve A Lowery et al.   JNCI-Journal of the National Cancer Institute

The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations

(2018) Liang Chen et al.   MOLECULAR CELL

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers

(2018) Michael Seiler et al.   NATURE MEDICINE

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma

(2018) Zhe Li et al.   Nature Communications

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

(2018) Andrew J Aguirre et al.   Cancer Discovery

Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing

(2018) Sarah V. Gerhart et al.   Scientific Reports

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

(2018) Maeve A Lowery et al.   JNCI-Journal of the National Cancer Institute

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.

(2018) Stephen V. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Intron retention is a source of neoepitopes in cancer

(2018) Alicia C Smart et al.   NATURE BIOTECHNOLOGY

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes

(2018) Pierre-Jacques Hamard et al.   Cell Reports

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

(2018) Francesco Puleo et al.   GASTROENTEROLOGY

LKB1 regulates PRMT5 activity in breast cancer

(2018) Hanine Lattouf et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth

(2018) Shikui Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Arginine methylation controls the strength of γc-family cytokine signaling in T cell maintenance

(2018) Maia Inoue et al.   NATURE IMMUNOLOGY

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

PRMT5 is essential for B cell development and germinal center dynamics

(2018) Ludivine C. Litzler et al.   Nature Communications

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

(2018) Aslamuzzaman Kazi et al.   Nature Communications

IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma

(2018) Giulia Biffi et al.   Cancer Discovery

Underestimation of pancreatic cancer in the national cancer registry – Reconsidering the incidence and survival rates

(2017) J. Fest et al.   EUROPEAN JOURNAL OF CANCER

The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy

(2017) Dai Shimizu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination

(2017) Thomas L. Clarke et al.   MOLECULAR CELL

Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases

(2017) Kanishk Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome

(2017) Cara Lunn Shirai et al.   Nature Communications

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing

(2017) Jiawei Zhao et al.   Scientific Reports

PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression

(2017) Kelly Chiang et al.   Cell Reports

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts

(2017) Rémy Nicolle et al.   Cell Reports

Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation

(2016) Esther A. Obeng et al.   CANCER CELL

Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth

(2016) L. Liu et al.   CANCER RESEARCH

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia

(2016) Yanli Jin et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins

(2016) Stanley Chun-Wei Lee et al.   NATURE MEDICINE

PRMT5–PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells

(2016) Y K Banasavadi-Siddegowda et al.   ONCOGENE

Asymmetric arginine dimethylation of RelA provides a repressive mark to modulate TNFα/NF-κB response

(2016) Anja Reintjes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

(2016) Konstantinos J. Mavrakis et al.   SCIENCE

MTAPdeletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

(2016) Gregory V. Kryukov et al.   SCIENCE

Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer

(2016) Jian-xin Jiang et al.   TUMOR BIOLOGY

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

(2016) Katya Marjon et al.   Cell Reports

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) M. Ducreux et al.   ANNALS OF ONCOLOGY

Identification of germline genetic mutations in patients with pancreatic cancer

(2015) Erin E. Salo-Mullen et al.   CANCER

Detained introns are a novel, widespread class of post-transcriptionally spliced introns

(2015) Paul L. Boutz et al.   GENES & DEVELOPMENT

The spliceosome is a therapeutic vulnerability in MYC-driven cancer

(2015) Tiffany Y.-T. Hsu et al.   NATURE

MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis

(2015) Cheryl M. Koh et al.   NATURE

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

(2015) Elayne Chan-Penebre et al.   Nature Chemical Biology

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells

(2015) J Chakedis et al.   ONCOGENE

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells

(2015) S Calabretta et al.   ONCOGENE

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

(2015) A Sveen et al.   ONCOGENE

Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis

(2015) Dong Hu et al.   Nature Communications

Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing

(2015) Li Zhang et al.   eLife

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma

(2014) Chinbold Enkhbold et al.   HEPATOLOGY RESEARCH

Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery

(2013) M. Bezzi et al.   GENES & DEVELOPMENT

Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma

(2013) Dusten Unruh et al.   INTERNATIONAL JOURNAL OF CANCER

Arginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1

(2013) Shunsheng Zheng et al.   MOLECULAR CELL

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases

(2013) J Ueda et al.   ONCOGENE

PRMT5 dimethylates R30 of the p65 subunit to activate NF- B

(2013) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs

(2013) Surbhi Dhar et al.   Scientific Reports

Protein arginine methyltransferase 5 is essential for growth of lung cancer cells

(2012) Zhongping Gu et al.   BIOCHEMICAL JOURNAL

Arginine methylation controls growth regulation by E2F-1

(2012) Er-Chieh Cho et al.   EMBO JOURNAL

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

(2012) Michael A Jacobetz et al.   GUT

The spliceosome as a target of novel antitumour drugs

(2012) Sophie Bonnal et al.   NATURE REVIEWS DRUG DISCOVERY

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway

(2012) Azadeh Arabi et al.   Nature Communications

Down-Regulation of Methylthioadenosine Phosphorylase ( MTAP ) Induces Progression of Hepatocellular Carcinoma via Accumulation of 5′-Deoxy-5′-Methylthioadenosine (MTA)

(2011) Georgi Kirovski et al.   AMERICAN JOURNAL OF PATHOLOGY

Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma

(2011) J Kurashige et al.   BRITISH JOURNAL OF CANCER

FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation

(2011) Roya Babaei-Jadidi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation

(2011) Jung-Mao Hsu et al.   NATURE CELL BIOLOGY

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein Arginine Methyltransferase 5 Regulates ERK1/2 Signal Transduction Amplitude and Cell Fate Through CRAF

(2011) P. Andreu-Perez et al.   Science Signaling

Versatility of PRMT5-induced methylation in growth control and development

(2011) Vrajesh Karkhanis et al.   TRENDS IN BIOCHEMICAL SCIENCES

Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients

(2010) Mutsuko Ibusuki et al.   CANCER SCIENCE

PRMT5 regulates Golgi apparatus structure through methylation of the golgin GM130

(2010) Zhongwei Zhou et al.   CELL RESEARCH

KLF4α Up-regulation Promotes Cell Cycle Progression and Reduces Survival Time of Patients With Pancreatic Cancer

(2010) Daoyan Wei et al.   GASTROENTEROLOGY

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged

(2010) C. J. David et al.   GENES & DEVELOPMENT

Methylation of Ribosomal Protein S10 by Protein-arginine Methyltransferase 5 Regulates Ribosome Biogenesis

(2010) Jinqi Ren et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

(2010) Thomas Ernst et al.   NATURE GENETICS

p53-Altered FBXW7 Expression Determines Poor Prognosis in Gastric Cancer Cases

(2009) T. Yokobori et al.   CANCER RESEARCH

Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance

(2009) Masaaki Iwatsuki et al.   INTERNATIONAL JOURNAL OF CANCER

Protein Arginine Methylation in Mammals: Who, What, and Why

(2009) Mark T. Bedford et al.   MOLECULAR CELL

A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies

(2008) Lisa Berglund et al.   MOLECULAR & CELLULAR PROTEOMICS

Arginine methylation regulates the p53 response

(2008) Martin Jansson et al.   NATURE CELL BIOLOGY